Allogene Therapeutics Inc

NASDAQ:ALLO

1.19

-0.01 (-0.83%)

4:56:56 PM EDT: $1.17 -0.02 (-1.68%)

Allogene Therapeutics Inc Stock, NASDAQ:ALLO

210 East Grand Avenue, South San Francisco, California 94080-4811

United States of America

Phone: +1.650.457.2700

Number of Employees: 229

http://www.allogene.com

Description

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.